Prokidney

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Prokidney sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 2 currently recruiting 4 completed early-phase tilt upper quartile by trial count

Prokidney: 8 sponsored US clinical trials, 2 recruiting.

Prokidney sponsors 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 2 Diabetes Mellitus, with 2 trials.

Upper-quartile sponsor footprint

Prokidney sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING

A Long-Term Follow-Up Study of Participants Exposed to REACT

NCT05918523
RECRUITING Phase 3

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

NCT05099770
TERMINATED Phase 1

A Study of Participants With Chronic Kidney Disease Previously Treated With REACT

NCT05694169
COMPLETED Phase 2

Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)

NCT05018416
COMPLETED Phase 1

A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).

NCT04115345
COMPLETED Phase 2

A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease

NCT03270956
COMPLETED Phase 2

A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease

NCT02836574
TERMINATED Phase 2

Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)

NCT02525263

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 1

Therapeutic Areas

Type 2 Diabetes Mellitus 2
Chronic Kidney Diseases 2
Chronic Kidney Disease 1
Diabetic Kidney Disease 1

What is open in the Prokidney pipeline

2 recruiting of 8 indexed (25% open); 4 completed (50%).

Phase mix: 1 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Type 2 Diabetes Mellitus (2 trials), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Prokidney: open-pipeline peers nationwide

Peers matched on 8 registered trials and 25% open enrollment, not the therapeutic-area sidebar.

Prokidney sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 3456789 0%10%20%30%40% Total trials Recruiting share ProkidneyAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Abdul Latif Jameel Poverty Action LabAccutar BiotechnologyAdrienne G. WaksAdvocate Hospital System
Prokidney sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Prokidney sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 25% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Prokidney page

8 registered trials is a research-attention snapshot, not an endorsement of Prokidney or any single study.

  • 2 of Prokidney's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Type 2 Diabetes Mellitus is the condition Prokidney studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 2 Diabetes Mellitus trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Prokidney pipeline card: 8 registered trials from official public datasets.Report a data error.